ジェネリック注射剤の世界市場（2022年版）-分子タイプ別、（小型、大型）、治療領域、容器タイプ、地域別、国別の分析COVID-19の影響を受けた市場のインサイトと予測（2022-2027年）

Global Generic Injectables Market (2022 Edition) – Analysis By Molecule Type, (Small, Large), Therapeutic Area, Container Type, By Region, By Country: Market Insights and Forecast with Impact of COVID-19 (2022-2027)

エグゼクティブサマリージェネリック注射剤の世界市場規模は2021年に1340億米ドルとなり、北米地域が地域別シェアをリードしています。ジェネリック注射剤市場の成長を促す主な要因としては、ブランド薬の特... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2022年2月28日	US$2,400 シングルユーザーライセンスライセンス・価格情報注文方法はこちら	240	英語

サマリー

エグゼクティブサマリー

ジェネリック注射剤の世界市場規模は2021年に1340億米ドルとなり、北米地域が地域別シェアをリードしています。ジェネリック注射剤市場の成長を促す主な要因としては、ブランド薬の特許切れ、ジェネリック注射剤の承認件数増加、高齢者人口の増加、世界人口における生命を脅かす疾患の有病率上昇などが挙げられます。また、ブランド薬のコストに比べ、ジェネリック医薬品は比較的安価であり、がん、循環器疾患、糖尿病などの主要疾患の治療に使用されるため、市場の需要をさらに後押ししています。

アジア太平洋地域は、インド企業が複合型ジェネリック医薬品に注力するようになったことや、費用対効果の高さからジェネリック注射剤の採用が増加していることから、最も成長率の高い地域と推定されます。また、APAC諸国（中国、インド）はさまざまな慢性疾患の有病率が最も高く、今後数年間の市場成長を促進すると予測されます。一方、ジェネリック注射剤の世界市場においては、北米が引き続き支配的な地域となるでしょう。北米地域の米国とアジア太平洋地域の中国が、世界のジェネリック医薬品市場の主要国となっています。

COVID-19の発生は、病院、医療サービス、医薬品メーカーに大きな影響を与え、社会的距離、旅行制限、国境閉鎖、集会制限、在宅勤務など、世界各国の政府による様々な制約を受けたため、世界のジェネリック注射剤市場に影響を及ぼしました。COVID-19は、需要と供給の両方に直接的な影響を与え、多くの注射剤が時間通りに市場に出回ることができず、サプライチェーンに混乱が生じました。製薬業界におけるCOVID-19の影響は、他の業界と比べるとやや少ないものの、それでもいくつかの点で被害を受けている。パンデミックのために、研究者が研究所を訪れることができず、進行中の臨床試験を継続することができなかったため、多くの臨床試験が遅れた。もし混乱がなければ、これらの分子は特許分子として市場に出てくるでしょうから、予測期間中にジェネリック注射剤市場が拡大することになります。

ファイザー株式会社は、複数のジェネリック注射薬の導入や地域の製薬会社との合併・提携により、その地位を強化してきた世界有数のジェネリック注射薬企業です。最近では2021年にファイザー社がアメリカの製薬会社イーライリリー・アンド・カンパニーと提携し、変形性関節症の痛みを治療するジェネリック注射薬「タネツマブ」のアメリカでの承認を発表しています。今後、特許が切れるブランド薬が増える中、ファイザーはそれらの注射薬のジェネリック医薬品を開発し、FDAの承認を得て市場に投入する明確な計画を立てています。

報告書の範囲

- このレポートは、ジェネリック注射剤市場を金額（10億米ドル）別に分析しています。

- 本レポートでは、2017年～2021年の過去期間と2022年～2027年の予測期間におけるジェネリック注射剤市場の分析をご紹介しています。

- このレポートでは、ジェネリック注射剤市場を分子タイプ（低分子、高分子）別に分析しています。

- 当レポートでは、ジェネリック注射剤市場を治療領域別（がん、抗感染症、循環器、糖尿病、その他）に分析しています。

- このレポートでは、ジェネリック注射剤市場を容器別（バイアル、アンプル、プレフィルドシリンジ、その他）に分析しています。

- ジェネリック注射剤の世界市場は、地域別（北米、欧州、アジア太平洋、LAMEA）に分析されています。

- ジェネリック注射剤の世界市場は国別（米国、カナダ、ドイツ、英国、フランス、イタリア、中国、日本、インド、オーストラリア）に分析されています。

- 本レポートの主要な洞察は、SWOT分析の枠組みを通じて提示されています。また、市場の魅力は、地域別、分子タイプ別、治療分野別、容器別に提示されています。

- また、業界の主な機会、トレンド、ドライバー、課題についても分析されています。

- 本レポートでは、競合他社の動向、戦略、2021年におけるジェネリック注射剤の初回承認リストを追跡しています。本レポートで分析している企業は、ファイザー株式会社、ノバルティス、サノフィ、バクスターインターナショナル、Fresenius SE & Co KGaA、Amneal Pharmaceuticals、ヒグマ製薬、グランドファーマ、テバ製薬、日興製薬などです。

主な対象読者

- 注射剤メーカーおよび販売代理店

- 製薬会社、バイオ製薬会社、バイオテクノロジー会社

- エンドユーザー（病院、外来手術センター、診断センター、その他）

- 研究開発（R&D）機関

- 政府機関および規制当局

- 投資銀行・エクイティファーム

ページTOPに戻る

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Generic Injectables Market: Product Overview

4. Global Generic Injectables Market: An Analysis

4.1 Market Size, By Value, 2017-2027

4.2 Global Generic Injectables Market: Growth & Forecast

4.3 Impact of COVID-19 on Generic Injectables Market

5. Global Generic Injectables Market Segmentation, By Molecule Type (Value)

5.1 Competitive Scenario of Global Generic Injectables Market: By Molecule Type

5.2 Global Generic Injectables Market: Segment Analysis

5.3 By Small Molecule - Market Size and Forecast (2017-2027)

5.4 By Large Molecule - Market Size and Forecast (2017-2027)

6. Global Generic Injectables Market Segmentation, By Therapeutic Area (Value)

6.1 Competitive Scenario of Global Generic Injectables Market: By Therapeutic Area (2021 & 2027)

6.2 Global Generic Injectables Market: Segment Analysis

6.3 By Oncology - Market Size and Forecast (2017-2027)

6.4 By Anti-infectives - Market Size and Forecast (2017-2027)

6.5 By Cardiovascular - Market Size and Forecast (2017-2027)

6.6 By Diabetes - Market Size and Forecast (2017-2027)

6.7 By Others - Market Size and Forecast (2017-2027)

7. Global Generic Injectables Market Segmentation, By Container (Value)

7.1 Competitive Scenario of Global Generic Injectables Market: By Container (2021 & 2027)

7.2 Global Generic Injectables Market: Segment Analysis

7.3 By Vials - Market Size and Forecast (2017-2027)

7.4 By Ampoules - Market Size and Forecast (2017-2027)

7.5 By Pre-filled Syringes - Market Size and Forecast (2017-2027)

7.6 By Others - Market Size and Forecast (2017-2027)

8. Global Generic Injectables Market: Regional Analysis

8.1 Competitive Scenario of Global Generic Injectables Market: By Region (2021 & 2027)

9. North America Generic Injectables Market: An Analysis (2017-2027)

9.1 North America Generic Injectables Market: Size and Forecast (2017-2027), By Value

9.2 North America Generic Injectables Market - Prominent Companies

9.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)

9.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)

9.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)

9.6 North America Generic Injectables Market: Country Analysis

9.7 Market Opportunity Chart of North America Generic Injectables Market - By Country, By Value (Year-2026)

9.8 Competitive Scenario of North America- By Country

9.9 United States Generic Injectables Market: Size and Forecast (2017-2027), By Value

9.10 United States Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

9.11 Canada Generic Injectables Market: Size and Forecast (2017-2027), By Value

9.12 Canada Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

10. Europe Generic Injectables Market: An Analysis (2017-2027)

10.1 Europe Generic Injectables Market by value: Size and Forecast (2017-2027)

10.2 Europe Generic Injectables Market: Prominent Companies

10.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)

10.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)

10.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)

10.6 Europe Generic Injectables Market: Country Analysis

10.7 Market Opportunity Chart of Europe Generic Injectables Market - By Country, By Value (Year-2026)

10.8 Competitive Scenario of Europe Generic Injectables Marketñ By Country (2021 & 2027)

10.9 Germany Generic Injectables Market: Size and Forecast (2017-2027)

10.10 Germany Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

10.11 United Kingdom Generic Injectables Market: Size and Forecast (2017-2027)

10.12 United Kingdom Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

10.13 France Generic Injectables Market: Size and Forecast (2017-2027)

10.14 France Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

10.15 Italy Generic Injectables Market: Size and Forecast (2017-2027)

10.16 Italy Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

11. Asia Pacific Generic Injectables Market: An Analysis (2017-2027)

11.1 Asia Pacific Generic Injectables Market by value: Size and Forecast (2017-2027)

11.2 Asia Pacific Generic Injectables Market: Prominent Companies

11.3 Market Segmentation By Molecule Type (Small Molecule and Large Molecule)

11.4 Market Segmentation By Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes and Others)

11.5 Market Segmentation By Container (Vials, Ampoules, Pre-filled Syringes and Others)

11.6 Asia Pacific Generic Injectables Market: Country Analysis

11.7 Market Opportunity Chart of Asia Pacific Generic Injectables Market - By Country, By Value (Year-2026)

11.8 Competitive Scenario of Asia Pacific Generic Injectables Market - By Country (2021 & 2027)

11.9 China Generic Injectables Market: Size and Forecast (2017-2027)

11.10 China Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

11.11 Japan Generic Injectables Market: Size and Forecast (2017-2027)

11.12 Japan Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

11.13 India Generic Injectables Market: Size and Forecast (2017-2027)

11.14 India Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

11.15 Australia Generic Injectables Market: Size and Forecast (2017-2027)

11.16 Australia Generic Injectables Market Segmentation By Molecule Type, By Therapeutic Area and By Container (2017-2027)

12. Global Generic Injectables Market Dynamics

12.1 Global Generic Injectables Market Drivers

12.2 Global Generic Injectables Market Restraints

12.3 Global Generic Injectables Market Trends

13. Market Attractiveness and Strategic Analysis

13.1 Market Attractiveness Chart of Global Generic Injectables Market - By Molecule Type (Year 2027)

13.2 Market Attractiveness Chart of Global Generic Injectables Market - By Therapeutic Area (Year 2027)

13.3 Market Attractiveness Chart of Global Generic Injectables Market ñ By Container (Year 2027)

13.4 Market Attractiveness Chart of Global Generic Injectables Market ñ By Region (Year 2027)

14. Competitive Landscape

14.1 Market Share of global leading companies

14.2 Market Share of Leading US Companies by Value & by Volume

14.3 SWOT Analysis - Global Generic Injectables Market

15. Global Generic Injectables Market: List of First-Time Generic Injectables Approvals in 2021

16. Company Profiles (Business Description, Financial Analysis, Business Strategy)

16.1 Pfizer Inc.

16.2 Novartis

16.3 Sanofi

16.4 Baxter International

16.5 Fresenius SE & Co KGaA

16.6 Amneal Pharmaceuticals

16.7 Hikma Pharmaceuticals

16.8 Gland Pharma

16.9 Teva Pharmaceuticals

16.10 Nichi-iko Pharmaceutical

List of Figures

Figure 1: Global Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 2: Global Estimated number of Cancer incidences and prevalent cases (all ages, in millions), Year 2020

Figure 3: Global Cancer related number of deaths (all ages, in thousand's), Year 2020

Figure 4: Global Estimated number of Diabetes prevalent cases (adults (20-79), in millions), Year 2021

Figure 5: Global Prevalence of Cardiovascular Diseases, (in million), 2015-2019

Figure 6: Global Aged Population (Above 65), 2015-20 (% of total Population)

Figure 7: Global Aged Population (Above 65), By Country, 2020 (% of total Population)

Figure 8: Global Medical Spending in 2020, By Region, (% of Total)

Figure 9: Current Healthcare Expenditure (% Share of GDP), By Selected Country, 2016-2020 (In %)

Figure 10: Global Expected Healthcare Industry Outlook

Figure 11: Regional Expected Healthcare Industry Growth Rate By Year 2024

Figure 12: Global Generic Injectables Market- By Molecule Type Market Share, 2021 & 2027

Figure 13: Global Generic Injectables Market- By Small Molecule, By Value (USD Billion), 2017-2027

Figure 14: Global Generic Injectables Market- By Large Molecule, By Value (USD Billion), 2017-2027

Figure 15: Global Generic Injectables Market - By Therapeutic Area Market Share, 2021 & 2027

Figure 16: Global Generic Injectables Market- By Oncology, By Value (USD Billion), 2017-2027

Figure 17: Global Generic Injectables Market- By Anti-infectives, By Value (USD Billion), 2017-2027

Figure 18: Global Generic Injectables Market- By Cardiovascular, By Value (USD Billion), 2017-2027

Figure 19: Global Generic Injectables Market- By Diabetes, By Value (USD Billion), 2017-2027

Figure 20: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027

Figure 21: Global Generic Injectables Market- By Container Market Share, 2021 & 2027

Figure 22: Global Generic Injectables Market- By Vials, By Value (USD Billion), 2017-2027

Figure 23: Global Generic Injectables Market- By Ampoules, By Value (USD Billion), 2017-2027

Figure 24: Global Generic Injectables Market- By Pre-filled Syringes, By Value (USD Billion), 2017-2027

Figure 25: Global Generic Injectables Market- By Others, By Value (USD Billion), 2017-2027

Figure 26: Global Generic Injectables Market- By Region Market Share, 2021 & 2027

Figure 27: North America Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 28: Prevalence of Cardiovascular Diseases in North America, (in million), 2015-2019

Figure 29: Cancer prevalence in North America (in million), Year 2020

Figure 30: Prevalence of Multiple Sclerosis in North America, (in 1000ís), 2015-2019

Figure 31: North America Diabetes Prevalence, By Country, 2020 (% of Population Aged 20-79)

Figure 32: North America Diabetes-related health expenditure per person, USD (Year 2021)

Figure 33: North America Current health expenditure per capita (current USD), 2014-18

Figure 34: North America Population ages 65 and above (% of total Population), 2016-20

Figure 35: North America Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 36: North America Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 37: North America Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 38: Market Opportunity Chart of North America Generic Injectables Market- By Country, By Value (Year-2027)

Figure 39: North America Generic Injectables Market- By Country Market Share, 2021 & 2027

Figure 40: United States Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 41: Prevalence of Cardiovascular Diseases in United States, (in million), 2015-2019

Figure 42: Prevalence of Multiple Sclerosis in United States, (in 1000ís), 2016-2019

Figure 43: Cancer prevalence in United States (in million), Year 2020

Figure 44: United States Current health expenditure per capita (current USD), 2016-2020

Figure 45: United States Population aged 65 and above (% of total Population), 2016-20

Figure 46: Estimated people with diabetes in United States (in millions), 2021-2045

Figure 47: United States Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 48: United States Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 49: United States Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 50: Canada Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 51: Prevalence of Cardiovascular Diseases in Canada, (in million), 2015-2019

Figure 52: Estimated number of Cancer Prevalent cases in Canada, 2020

Figure 53: Prevalence of Multiple sclerosis in Canada, (in 1000ís), 2016-2019

Figure 54: Canada Current health expenditure per capita (current USD), 2017-2021

Figure 55: Canada Population aged 65 and above (% of total Population), 2016-20

Figure 56: Estimated people with diabetes in Canada (in millions), 2021-2045

Figure 57: Canada Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 58: Canada Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 59: Canada Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 60: Europe Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 61: Europe Prevalence of Cardiovascular Diseases (in Million), 2015-2019

Figure 62: Prevalence of Osteoarthritis Diseases in Europe, (in Million), 2015-2019

Figure 63: Europe estimated number of Cancer prevalence (all ages, in Million), Year 2020

Figure 64: Europe Prevalence of Multiple Sclerosis, 2016-2019 (In 1000ís)

Figure 65: Europe Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)

Figure 66: Europe Current health expenditure per capita (current USD), 2015-18

Figure 67: Total expenditure on health per capita in European countries (in USD PPP), 2019

Figure 68: Population ages 65 and above (% of total Population) in European Countries, 2020

Figure 69: Europe Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 70: Europe Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 71: Europe Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 72: Market Opportunity Chart of Europe Generic Injectables Market- By Country, By Value (Year-2026)

Figure 73: Europe Generic Injectables Market- By Country Market Share, 2021 & 2027

Figure 74: Germany Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 75: Prevalence of Cardiovascular Diseases in Germany, (in million), 2015-2019

Figure 76: Estimated people with diabetes in Germany (in millions), 2021-2045

Figure 77: Prevalence of Multiple Sclerosis in Germany, (in 1000ís), 2016-2019

Figure 78: Germany Current health expenditure per capita (current USD), 2015-2019

Figure 79: Germany Population aged 65 and above (% of total Population), 2016-20

Figure 80: Germany, Estimated percentage of prevalent Cancer cases, 2020

Figure 81: Germany Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 82: Germany Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 83: Germany Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 84: United Kingdom Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 85: Estimated people with diabetes in United Kingdom (in millions), 2021-2045

Figure 86: United Kingdom, Estimated percentage of prevalent Cancer cases, 2020

Figure 87: Prevalence of Multiple Sclerosis in United Kingdom, (in 1000ís), 2015-2019

Figure 88: United Kingdom Current health expenditure per capita (current USD), 2015-2019

Figure 89: United Kingdom Population aged 65 and above (% of total Population), 2016-20

Figure 90: Prevalence of Cardiovascular Diseases in United Kingdom, (in million), 2015-2019

Figure 91: United Kingdom Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 92: United Kingdom Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 93: United Kingdom Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 94: France Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 95: Estimated people with diabetes in France (in millions), 2021-2045

Figure 96: France, Estimated percentage of prevalent Cancer cases, 2020

Figure 97: Prevalence of Multiple Sclerosis in France, (in 1000ís), 2015-2019

Figure 98: France Current health expenditure per capita (current USD), 2015-2019

Figure 99: France Population aged 65 and above (% of total Population), 2016-20

Figure 100: Prevalence of Cardiovascular Diseases in France, (in million), 2015-2019

Figure 101: France Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 102: France Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 103: France Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 104: Italy Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 105: Estimated people with diabetes in Italy (in millions), 2021-2045

Figure 106: Italy, Estimated percentage of prevalent Cancer cases, 2020

Figure 107: Prevalence of Multiple Sclerosis in Italy, (in 1000ís), 2015-2019

Figure 108: Italy Current health expenditure per capita (current USD), 2015-2019

Figure 109: Italy Population aged 65 and above (% of total Population), 2016-20

Figure 110: Prevalence of Cardiovascular Diseases in Italy, (in million), 2015-2019

Figure 111: Italy Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 112: Italy Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 113: Italy Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 114: Asia Pacific Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 115: Prevalence of Cardiovascular Diseases in Asia Pacific, (in million), 2015-2019

Figure 116: Cancer prevalence in Asia Pacific (in thousands), Year 2020

Figure 117: Asia Pacific Diabetes Prevalence, By Country, 2020 (% of Population Aged 20 to 79)

Figure 118: Asia Pacific Current health expenditure per capita (current USD), 2014-18

Figure 119: Asia Pacific, Current health expenditure per capita, by countries (current USD), 2019

Figure 120: Asia Pacific, Population ages 65 and above (% of total Population), 2016-20

Figure 121: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020

Figure 122: Asia Pacific Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 123: Asia Pacific Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 124: Asia Pacific Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 125: Market Opportunity Chart of Asia Pacific Generic Injectables Market- By Country, By Value (Year-2026)

Figure 126: Asia Pacific Generic Injectables Market- By Country Market Share, 2021 & 2027

Figure 127: China Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 128: Estimated people with diabetes in China (in millions), 2021-2045

Figure 129: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 130: Estimated number of Cancer prevalent cases in China (all ages, in 1000ís), Year 2020

Figure 131: China Current health expenditure per capita (current USD), 2015-2019

Figure 132: China Population aged 65 and above (% of total Population), 2016-20

Figure 133: China Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 134: China Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 135: China Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 136: Japan Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 137: Estimated people with diabetes in Japan (in millions), 2021-2045

Figure 138: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)

Figure 139: Estimated number of Cancer prevalent cases in Japan (all ages, in 1000ís), Year 2020

Figure 140: Japan Healthcare Expenditure Outlook (%)

Figure 141: Japan Population aged 65 and above (% of total Population), 2016-20

Figure 142: Japan Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 143: Japan Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 144: Japan Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 145: India Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 146: Estimated people with diabetes in India (in millions), 2021-2045

Figure 147: Estimated number of Cancer prevalent cases in India (all ages, in 1000ís), Year 2020

Figure 148: Prevalence of Multiple Sclerosis in India, (in 1000ís), 2016-2019

Figure 149: Estimated value of public health spending in India (from 2017-20, in billions USD)

Figure 150: India Population aged 65 and above (% of total Population), 2016-20

Figure 151: Prevalence of Cardiovascular Diseases in India, (in million), 2015-2019

Figure 152: India Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 153: India Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 154: India Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 155: Australia Generic Injectables Market Size, By Value, 2017-2027 (USD Billion)

Figure 156: Estimated people with diabetes in Australia (in millions), 2021-2045

Figure 157: Estimated number of Cancer prevalent cases in Australia (all ages, in 1000ís), Year 2020

Figure 158: Prevalence of Multiple Sclerosis in Australia, (in 1000ís), 2016-2019

Figure 159: Australia Current health expenditure per capita (current USD), 2015-2019

Figure 160: Australia Population aged 65 and above (% of total Population), 2016-20

Figure 161: Prevalence of Cardiovascular Diseases in Australia, (in million), 2015-2019

Figure 162: Australia Generic Injectables Market- By Molecule Type, By Value (USD Billion), 2017-2027

Figure 163: Australia Generic Injectables Market- By Therapeutic Area, By Value (USD Billion), 2017-2027

Figure 164: Australia Generic Injectables Market- By Container, By Value (USD Billion), 2017-2027

Figure 165: Market Attractiveness Chart of Global Generic Injectables Market- By Molecule Type (Year-2027)

Figure 166: Market Attractiveness Chart of Global Generic Injectables Market- By Therapeutic Area (Year-2027)

Figure 167: Market Attractiveness Chart of Global Generic Injectables Market- By Container (Year-2027)

Figure 168: Market Attractiveness Chart of Global Generic Injectables Market- By Region (Year-2027)

Figure 169: Global Generic Injectables company market share (%), 2021

Figure 170: Market share in generic injectables in US (by value), 2021

Figure 171: Market share in generic injectables in US (by volume), 2021

Figure 172: Pfizer Inc. Annual Sales Revenue, 2016-2020 (USD Million)

Figure 173: Pfizer Inc. Net Income, 2016-2020 (USD Million)

Figure 174: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020

Figure 175: Novartis Annual Sales Revenue (USD Million), 2016-2020

Figure 176: Novartis Annual Net Income/Loss (USD Million), 2016-2020

Figure 177: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020

Figure 178: Novartis Sales Revenue Split, By Geography Segment (%), FY2020

Figure 179: Sanofi Sales Revenues, 2016-2020 (USD Million)

Figure 180: Sanofi Gross Profit, 2016-2020 (USD Million)

Figure 181: Sanofi Sales Revenue Split, By Business Segment (%), FY2020

Figure 182: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020

Figure 183: Baxter International Sales Revenues, 2016-2020 (USD Million)

Figure 184: Baxter International Net Income, 2016-2020 (USD Million)

Figure 185: Baxter International Sales Revenue Split, By Business Segment (%), FY2020

Figure 186: Baxter International Sales Revenue Split, By Geography Segment (%), FY2020

Figure 187: Fresenius SE & Co KGaA Sales Revenues, 2016-2020 (USD Million)

Figure 188: Fresenius SE & Co KGaA Net Income, 2016-2020 (USD Million)

Figure 189: Fresenius SE & Co KGaA Sales Revenue Split, By Business Segment (%), FY2020

Figure 190: Fresenius SE & Co KGaA Sales Revenue Split, By Geography Segment (%), FY2020

Figure 191: Amneal Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)

Figure 192: Amneal Pharmaceuticals Net Income, 2016-2020 (USD Million)

Figure 193: Amneal Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020

Figure 194: Amneal Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020

Figure 195: Hikma Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)

Figure 196: Hikma Pharmaceuticals Net Income, 20016-2020 (USD Million)

Figure 197: Hikma Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020

Figure 198: Hikma Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020

Figure 199: Gland Pharma Annual Sales Revenue (USD Million), 2017-2020

Figure 200: Gland Pharma Net Income (USD Million), 2017-2020

Figure 201: Gland Pharma Sales Revenue, By Business Segment (%), FY2020

Figure 202: Gland Pharma Sales Revenue, By Geographical Segment (%), FY2020

Figure 203: Teva Pharmaceuticals Sales Revenues, 2016-2020 (USD Million)

Figure 204: Teva Pharmaceuticals Net Income, 2016-2020 (USD Million)

Figure 205: Teva Pharmaceuticals Sales Revenue Split, By Business Segment (%), FY2020

Figure 206: Teva Pharmaceuticals Sales Revenue Split, By Geography Segment (%), FY2020

Figure 207: Nichi-iko Pharmaceutical Sales Revenues, 2016-2020 (USD Million)

Figure 208: Nichi-iko Pharmaceutical Net Income, 2016-2020 (USD Million)

Figure 209: Nichi-iko Pharmaceutical Sales Revenue Split, By Business Segment (%), FY2020

Figure 210: Nichi-iko Pharmaceutical Sales Revenue Split, By Geography Segment (%), FY2020

ページTOPに戻る

Table of Contents

Summary

Executive Summary

The global generic injectables market was valued at USD 134 billion in the year 2021 with the North American region leading the regional market share. Some of the key factors driving the generic injectables market growth are the expiration of branded drug patents, rising approvals for generic injectable drugs, rising aged population and the rising prevalence of life-threatening diseases among the global population. In addition, as compared to the costs of branded drugs, generic injectables are relatively inexpensive and used in the treatment of major diseases such as cancer, cardiovascular diseases, diabetes, and so on that further supports market demand.

The Asia Pacific is estimated to be the fastest-growing region due to the growing focus of Indian companies on complex generics and the rise in the adoption of generic injectables due to its cost-efficient nature. In addition, the APAC countries (China and India) have the highest prevalent cases of different chronic diseases, which is projected to fuel the market growth in upcoming years. Meanwhile, North America will remain the dominant region in the global Generic Injectables market. The United States in the North American region and China in Asia-Pacific are the major countries in the Generic Injectables market globally.

The outbreak of COVID-19 showed an impact on the global generic injectables market because hospitals, healthcare services, and drug manufacturers were significantly affected due to a variety of restrictions imposed by governments across the globe such as social distancing, travel restrictions, border closures, restrictions on public gatherings, work from home and so on. COVID-19 has had a direct impact on both supply and demand and created disruption in the supply chain, as many injectable drugs could not reach the market on time. Although the impact of COVID-19 in the pharmaceutical industry was a bit lesser compared to other industries, it still has been harmed in some ways. Many clinical trials were delayed due to the pandemic, as researchers were not permitted to visit the laboratories and continue those ongoing trials. If there were no disruptions, those molecules would come into the market as a patented molecule, hence increasing the generic injectables market in the forecast period.

Pfizer Inc. is the world's leading generic injectables company, having strengthened its position through the introduction of several generic injectable drugs as well as mergers & partnerships with regional pharma companies. Recently in 2021, Pfizer Inc. partnered with Eli Lilly and Company, an American pharmaceutical company, to announce the approval of tanezumab, a generic injectable drug for treating osteoarthritis pain in the United States. With more branded drugs coming off patent in the coming years, Pfizer has a clear plan to develop generic versions of those injectables and obtain FDA approvals to bring them to market.

Scope of the Report

• The report analyses the Generic Injectables Market by Value (USD Billion).

• The report presents the analysis of Generic Injectables Market for the historical period of 2017-2021 and the forecast period of 2022-2027.

• The report analyses the Generic Injectables Market by Molecule Type (Small Molecule, Large Molecule).

• The report analyses the Generic Injectables Market by Therapeutic Area (Oncology, Anti-infectives, Cardiovascular, Diabetes, Others)

• The report analyses the Generic Injectables Market by Container (Vials, Ampoules, Pre-filled Syringes and Others)

• The Global Generic Injectables Market has been analysed By Region (North America, Europe, Asia Pacific, and LAMEA).

• The Global Generic Injectables Market has been analysed By Country (United States, Canada, Germany, United Kingdom, France, Italy, China, Japan, India, Australia).

• The key insights of the report have been presented through the frameworks of SWOT Analysis. Also, the attractiveness of the market has been presented by region, by Molecule Type, by Therapeutic Area and by Container.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, and a List of First-Time Generic Injectables Approvals in 2021. The companies analysed in the report include Pfizer Inc., Novartis, Sanofi, Baxter International, Fresenius SE & Co KGaA, Amneal Pharmaceuticals, Hikma Pharmaceuticals, Gland Pharma, Teva Pharmaceuticals and Nichi-iko Pharmaceutical.

Key Target Audience

• Injectable Drug Manufacturers & Distributors

• Pharmaceutical, Biopharmaceutical & Biotechnological Companies

• End Users (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers & Others)

• Research and Development (R&D) Organizations

• Government Bodies & Regulating Authorities

• Investment Banks and Equity Firms

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（貨物運輸）の最新刊レポート

Azoth Analytics社の貨物運輸分野での最新刊レポート

本レポートと同じKEY WORD（generic）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

ジェネリック注射剤の世界市場（2022年版）-分子タイプ別、（小型、大型）、治療領域、容器タイプ、地域別、国別の分析COVID-19の影響を受けた市場のインサイトと予測（2022-2027年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（貨物運輸）の最新刊レポート

Azoth Analytics社の貨物運輸分野での最新刊レポート

本レポートと同じKEY WORD（generic）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?